- Home
- FULT vs CELC Comparison
FULT vs CELC Comparison
Compare FULT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FULT | CELC |
|---|---|---|
| Founded | 1882 | 2011 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | FULT | CELC |
|---|---|---|
| Price | $21.69 | $120.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $21.75 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 2.0M | 649.3K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.39 | N/A |
| Revenue Next Year | $5.52 | $720.19 |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.31 | $9.64 |
| 52 Week High | $22.99 | $129.09 |
Technical Indicators
Market Signals| Indicator | FULT | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 52.76 |
| Support Level | $21.54 | $99.38 |
| Resistance Level | $21.92 | N/A |
| Average True Range (ATR) | 0.56 | 7.46 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 40.45 | 63.82 |
Price Performance
Historical ComparisonAbout FULT Fulton Financial Corporation
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.